South Dakota Investment Council Acquires 3,890 Shares of Thermo Fisher Scientific Inc. $TMO

South Dakota Investment Council boosted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 11.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 37,908 shares of the medical research company’s stock after buying an additional 3,890 shares during the quarter. South Dakota Investment Council’s holdings in Thermo Fisher Scientific were worth $18,633,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. J. Stern & Co. LLP increased its holdings in shares of Thermo Fisher Scientific by 58,006.4% during the 4th quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company’s stock worth $18,258,082,000 after acquiring an additional 31,455,105 shares during the last quarter. Norges Bank acquired a new stake in Thermo Fisher Scientific during the 4th quarter valued at $3,072,744,000. Auto Owners Insurance Co increased its holdings in shares of Thermo Fisher Scientific by 57,845.0% in the fourth quarter. Auto Owners Insurance Co now owns 2,427,896 shares of the medical research company’s stock valued at $1,406,844,000 after purchasing an additional 2,423,706 shares during the last quarter. T. Rowe Price Investment Management Inc. raised its position in shares of Thermo Fisher Scientific by 2,183.2% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,328,845 shares of the medical research company’s stock valued at $770,000,000 after purchasing an additional 1,270,643 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its stake in shares of Thermo Fisher Scientific by 19.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,701,353 shares of the medical research company’s stock worth $4,462,550,000 after buying an additional 1,230,872 shares during the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

TMO has been the topic of a number of research reports. KeyCorp reiterated an “overweight” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. Evercore set a $570.00 price objective on Thermo Fisher Scientific in a report on Monday, July 6th. Wall Street Zen downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Morgan Stanley lifted their price target on Thermo Fisher Scientific from $620.00 to $650.00 and gave the stock an “overweight” rating in a report on Friday, July 24th. Finally, Barclays boosted their price target on Thermo Fisher Scientific from $625.00 to $650.00 and gave the company an “overweight” rating in a research note on Friday, July 24th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $617.14.

Thermo Fisher Scientific Stock Performance

NYSE TMO opened at $577.38 on Thursday. The firm has a 50-day moving average price of $501.43 and a two-hundred day moving average price of $511.85. Thermo Fisher Scientific Inc. has a 12-month low of $435.27 and a 12-month high of $643.99. The company has a market capitalization of $214.56 billion, a P/E ratio of 31.06, a P/E/G ratio of 2.35 and a beta of 0.87. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. The company had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The firm’s quarterly revenue was up 10.5% on a year-over-year basis. During the same period in the previous year, the business earned $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Analysts anticipate that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be given a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is presently 10.11%.

Insider Activity

In other news, COO Gianluca Pettiti sold 400 shares of the stock in a transaction on Monday, July 27th. The stock was sold at an average price of $565.00, for a total transaction of $226,000.00. Following the sale, the chief operating officer directly owned 24,651 shares of the company’s stock, valued at approximately $13,927,815. This represents a 1.60% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.33% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.